1. Home
  2. LYRA vs ALUR Comparison

LYRA vs ALUR Comparison

Compare LYRA & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • ALUR
  • Stock Information
  • Founded
  • LYRA 2005
  • ALUR 2009
  • Country
  • LYRA United States
  • ALUR United States
  • Employees
  • LYRA N/A
  • ALUR N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • ALUR
  • Sector
  • LYRA Health Care
  • ALUR
  • Exchange
  • LYRA Nasdaq
  • ALUR Nasdaq
  • Market Cap
  • LYRA 15.0M
  • ALUR 18.0M
  • IPO Year
  • LYRA 2020
  • ALUR N/A
  • Fundamental
  • Price
  • LYRA $9.15
  • ALUR $2.57
  • Analyst Decision
  • LYRA Buy
  • ALUR Strong Buy
  • Analyst Count
  • LYRA 2
  • ALUR 3
  • Target Price
  • LYRA $16.00
  • ALUR $22.83
  • AVG Volume (30 Days)
  • LYRA 288.0K
  • ALUR 59.5K
  • Earning Date
  • LYRA 08-13-2025
  • ALUR 08-12-2025
  • Dividend Yield
  • LYRA N/A
  • ALUR N/A
  • EPS Growth
  • LYRA N/A
  • ALUR N/A
  • EPS
  • LYRA N/A
  • ALUR N/A
  • Revenue
  • LYRA $1,185,000.00
  • ALUR $28,304,000.00
  • Revenue This Year
  • LYRA N/A
  • ALUR N/A
  • Revenue Next Year
  • LYRA $1,286.17
  • ALUR $49.37
  • P/E Ratio
  • LYRA N/A
  • ALUR N/A
  • Revenue Growth
  • LYRA N/A
  • ALUR N/A
  • 52 Week Low
  • LYRA $3.81
  • ALUR $2.15
  • 52 Week High
  • LYRA $37.50
  • ALUR $33.75
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 44.26
  • ALUR 47.97
  • Support Level
  • LYRA $8.35
  • ALUR $2.40
  • Resistance Level
  • LYRA $9.36
  • ALUR $2.59
  • Average True Range (ATR)
  • LYRA 1.25
  • ALUR 0.13
  • MACD
  • LYRA -0.72
  • ALUR 0.01
  • Stochastic Oscillator
  • LYRA 9.95
  • ALUR 58.33

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Share on Social Networks: